Literature DB >> 17258000

Effects of cell-based angiogenic gene therapy at 6 months: persistent angiogenesis and absence of oncogenicity.

Christopher Kim1, Ren-Ke Li, Guangming Li, Yaoguang Zhang, Richard D Weisel, Terrence M Yau.   

Abstract

BACKGROUND: Transplantation of vascular endothelial growth factor (VEGF)-transfected cells into myocardial scar enhances angiogenesis and may support the transplanted cells. We evaluated the effect of cell type, time, and location on the durability of this angiogenesis and potential oncogenicity.
METHODS: Lewis rats underwent myocardial cryoinjury 3 weeks before transplantation with heart cells (HC [a mixed culture of cardiomyocytes, smooth muscle cells, endothelial cells, and fibroblasts]), VEGF-transfected heart cells (HC+), skeletal myoblasts (Sk), VEGF-transfected skeletal myoblasts (Sk+), or medium (control) (n = 3 per group x 5 groups x 5 timepoints). Three days, 1 week, 2 weeks, 4 weeks, and 6 months after transplantation, hearts were excised and the scar, border zone, and normal myocardium evaluated for angioma or sarcoma formation, and vascular density quantitated.
RESULTS: Vascular densities were lowest in controls, intermediate in HC and Sk (p < 0.05) and highest in HC+ and Sk+ (p < 0.05). Densities were highest in the border zone, intermediate in normal myocardium, and lowest in the scar (p < 0.05), peaking in the border zone of HC+ and Sk+ hearts at 4 weeks. At 6 months, densities were greater in HC and Sk than controls (p < 0.05), and higher in Sk+ than Sk (p < 0.05), but HC+ and HC were similar. There was no evidence of angioma or sarcoma formation at any timepoint.
CONCLUSIONS: Angiogenesis induced by HC and Sk transplantation lasts at least 6 months and is increased by transfection with VEGF without apparent oncogenicity. The durability of the VEGF effect on vascular densities may be greater with Sk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17258000     DOI: 10.1016/j.athoracsur.2006.09.044

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

Review 1.  Genetic enhancement of stem cell engraftment, survival, and efficacy.

Authors:  Marc S Penn; Abeel A Mangi
Journal:  Circ Res       Date:  2008-06-20       Impact factor: 17.367

2.  Non-invasive bioluminescence imaging of myoblast-mediated hypoxia-inducible factor-1 alpha gene transfer.

Authors:  Olivier Gheysens; Ian Y Chen; Martin Rodriguez-Porcel; Carmel Chan; Julia Rasooly; Caroline Vaerenberg; Ramasamy Paulmurugan; Juergen K Willmann; Christophe Deroose; Joseph Wu; Sanjiv S Gambhir
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

Review 3.  Proinflammatory stem cell signaling in cardiac ischemia.

Authors:  Jeremy L Herrmann; Troy A Markel; Aaron M Abarbanell; Brent R Weil; Meijing Wang; Yue Wang; Jiangning Tan; Daniel R Meldrum
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

4.  Myogenic endothelial cells purified from human skeletal muscle improve cardiac function after transplantation into infarcted myocardium.

Authors:  Masaho Okada; Thomas R Payne; Bo Zheng; Hideki Oshima; Nobuo Momoi; Kimimasa Tobita; Bradley B Keller; Julie A Phillippi; Bruno Péault; Johnny Huard
Journal:  J Am Coll Cardiol       Date:  2008-12-02       Impact factor: 24.094

5.  Topical negative pressure effects on coronary blood flow in a sternal wound model.

Authors:  Sandra Lindstedt; Malin Malmsjö; Bodil Gesslein; Richard Ingemansson
Journal:  Int Wound J       Date:  2008-10       Impact factor: 3.315

6.  Rapid analysis of vessel elements (RAVE): a tool for studying physiologic, pathologic and tumor angiogenesis.

Authors:  Marc E Seaman; Shayn M Peirce; Kimberly Kelly
Journal:  PLoS One       Date:  2011-06-09       Impact factor: 3.240

7.  No hypoperfusion is produced in the epicardium during application of myocardial topical negative pressure in a porcine model.

Authors:  Sandra Lindstedt; Malin Malmsjö; Richard Ingemansson
Journal:  J Cardiothorac Surg       Date:  2007-12-06       Impact factor: 1.637

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.